New York, USA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- DelveInsight’s report includes a comprehensive understanding of current treatment practices, emerging EGFR inhibitors-induced skin disorders drugs, market share of individual therapies, and current and forecasted EGFR inhibitors-induced skin disorders market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Discover which therapies are expected to grab the EGFR inhibitors-induced skin disorders market share @ EGFR inhibitors have revolutionized cancer treatment by targeting the pathways crucial for tumor growth.
However, a notable side effect of these medications is the development of skin disorders, which can significantly impact patients' quality of life. Common manifestations include acneiform rash, pruritus, xerosis, and paronychia. These reactions often occur within the first few weeks of treatment and can vary in severity from mild irritation to more severe cases requiring medical intervention.
The pathophysiology of EGFR inhibitor-induced skin toxicity involves the disruption of normal skin homeostasis due to the inhibition of EGFR signaling, which plays a critical role in skin cell growth and differentiation. The resulting inflammatory response leads to the characteristic rash seen in affected patients. Management typically involves symptomatic relief through topical therapies, such as moisturizers and corticosteroids, while dose adjustments or temporary cessation of treatment may be necessary in more severe cases.
Despite these challenges, advances in supportive care have improved outcomes, allowing patients to continue potentially life-saving therapies with minimized discomfort. The EGFR inhibitors-induced skin disorders epidemiology section provides insights into the historical and current EGFR inhibitors-induced skin disorders patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving EGFR inhibitors-induced skin disorders epidemiology trends @ The management of skin reactions associated with EGFR inhibitors lacks standardization, with literature accounts primarily reflecting local practices and extensive personal experience. At present, no approved therapy exists specifically for skin conditions caused by anti-EGFR treatments. Off-label therapeutic options include sunscreen, emollients, soap substitutes, antibiotics, antihistamines, topical steroids, and cosmetics.
Treatment with anti-EGFR agents often results in various dermatologic toxicities, such as skin rashes, abnormal hair growth, and eye abnormalities. For patients experiencing mild to moderate (Grade 1/2) skin reactions, these issues are typically managed with affordable emollient ointments and moisturizers, avoiding sun exposure and irritants, and taking short showers. In cases of moderate to severe skin toxicities, the use of topical steroid creams like hydrocortisone (0.
5%-2.5%), either alone or with topical emollients and moisturizers, may be necessary. If the skin toxicity leads to an infection, treatment with topical antibiotic ointments or systemic antibiotics is required.
Unlike acne vulgaris, it is advised to use topical antibiotics such as erythromycin, metronidazole, or nadifloxacin twice a day for early-stage and mild papulopustular skin reactions. Creams or lotions are preferred for their added moisturizing effect. To alleviate itching, skin moisturizers and lotions containing urea or polidocanol are used.
Fissures are managed by applying a 50% propylene glycol solution in water for 30 minutes under plastic occlusion each night, followed by a hydrocolloid dressing. Paronychia is treated with daily antiseptic baths to prevent bacterial superinfection. Learn more about the market of EGFR inhibitors-induced skin disorders @ The potential drugs in the pipeline include (Lutris Pharma) and (Hoth Therapeutics) for the treatment of EGFR inhibitors-induced skin disorders.
is a topical B-Raf inhibitor and a proprietary, first-in-class, small molecule. It is currently in a Phase II clinical trial for metastatic colorectal cancer patients with EGFR inhibitor-induced acneiform lesions and has completed a Phase I/II study for treating radiation-induced dermatitis in breast cancer patients. In February 2024, received an for LUT014 to treat EGFR-induced acneiform rash.
In April 2021, Lutris Pharma announced results from a Phase I study of LUT-014, evaluating its safety, tolerability, and efficacy for treating EGFR inhibitor-induced acneiform lesions in metastatic colorectal cancer patients. These results were published in Cancer Discovery, a journal of the American Association for Cancer Research. is developing a topical formulation to treat patients with mild to moderate rashes and skin disorders linked to initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor inhibitor therapy.
The ongoing Phase IIa CLEER clinical trial is assessing the safety and efficacy of in patients with these conditions. In January 2024, the company announced that it received the FDA approval to expand the HT-001 clinical trial to treat severely Ill patients. In January 2023, the FDA approved an investigational new drug (IND) application for HT-001 for the treatment of rash and skin disorders related to EGFR inhibitor therapy.
Additionally, in February 2022, Hoth Therapeutics announced a partnership with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to produce clinical batches of HT-001 for the upcoming CLEER-001 clinical trial for cancer patients. In December 2020, Hoth Therapeutics revealed a production agreement with Tergus Pharma for both GLP and GMP materials associated with HT-001 for its novel cancer treatment. The anticipated launch of these emerging therapies are poised to transform the EGFR inhibitors-induced skin disorders market landscape in the coming years.
As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the EGFR inhibitors-induced skin disorders market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about EGFR inhibitors-induced skin disorders clinical trials, visit @ The EGFR inhibitors-induced skin disorders market dynamics are anticipated to change in the coming years. The and globally increase the chances of EGFR inhibitor-induced skin disease, leading to a .
The is expected to fuel market growth. offers a of novel therapies, as medications with , and are the current unmet need in the anti-EGFR-induced skin diseases market. Furthermore, many potential therapies are being investigated for the treatment of EGFR inhibitors-induced skin disorders, and it is safe to predict that the treatment space will significantly impact the EGFR inhibitors-induced skin disorders market during the forecast period.
Moreover, the with improved efficacy and a further is expected to drive the growth of the EGFR inhibitors-induced skin disorders market in the 7MM. However, several factors may impede the growth of the EGFR inhibitors-induced skin disorders market. The , an for EGFR-induced skin toxicities, and , combined with , may hinder accurate , ultimately resulting in poor market access for emerging therapies.
Moreover, EGFR inhibitors-induced skin disorder treatment poses a and disrupts patients’ overall well-being and QOL. Furthermore, the EGFR inhibitors-induced skin disorders market growth may be offset by , , , and a . In addition, the about the disease may also impact the EGFR inhibitors-induced skin disorders market growth.
Discover more about EGFR inhibitors-induced skin disorders in development @ report delivers an in-depth understanding of the disease, historical and forecasted EGFR inhibitors-induced skin disorders epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HIV type-1 companies, including among others. report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key hand eczema companies, including among others. report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eczema companies, including among others.
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key eczema companies, including among others. DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
